Journal article
Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors’ Expert Forum
Abstract
In December 2008, the U.S. Food and Drug Administration issued guidance to the pharmaceutical industry setting new expectations for the development of antidiabetes drugs for type 2 diabetes. This guidance expanded the scope and cost of research necessary for approval of such drugs by mandating long-term cardiovascular outcomes trials (CVOTs) for safety. Since 2008, 9 CVOTs have been reported, 13 are under way, and 4 have been terminated. …
Authors
Cefalu WT; Kaul S; Gerstein HC; Holman RR; Zinman B; Skyler JS; Green JB; Buse JB; Inzucchi SE; Leiter LA
Journal
Diabetes Care, Vol. 41, No. 1, pp. 14–31
Publisher
American Diabetes Association
Publication Date
January 2018
DOI
10.2337/dci17-0057
ISSN
0149-5992
Associated Experts
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
AgedCardiovascular DiseasesCardiovascular SystemClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsEndpoint DeterminationFemaleFollow-Up StudiesGlucagon-Like Peptide-1 ReceptorGlycoside Hydrolase InhibitorsHumansHypoglycemic AgentsInsulinMaleMiddle AgedMortalityRandomized Controlled Trials as TopicRisk FactorsSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 InhibitorsTreatment OutcomeGlucagon-Like Peptide-1 Receptor Agonists